Migraines are more than just your typical headache and can get to the point where it prevents the person from doing anything for the rest of the day, or even days in some cases. There are several treatments available in the market, but they are not always effective. However the good news for migraine sufferers is that there is a new drug on the market that seems promising.
The FDA has recently announced that they have approved the sale of what can be described as the first FDA-approved preventive migraine drug called Aimovig. This is a drug that blocks the activity of calcitonin gene-related peptide, which is a molecule that is involved when it comes to migraine attacks.
So far based on the clinical tests that have been conducted, it seems that Aimovig has the ability to reduce the number of migraines occurring a month by 1-2 days, which is said to be a reduction of roughly 50%. It is not a cure but for those who do suffer from the occasional migraine, suffering 1-2 fewer migraine attacks every month is no doubt very much welcome.
Aimovig comes in form of a pen similar to an insulin pen where patients will be able to administer it themselves. However it will not come cheap and is expected to cost $575 a month, or $6,900 a year for those without insurance.